Theralase Technologies (FRA:TTX) 1-Year Share Buyback Ratio : -8.50% (As of Dec. 2024 )

View and export this data going back to 2014. Start your Free Trial

What is Theralase Technologies 1-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Theralase Technologies's current 1-Year Share Buyback Ratio was -8.50%.

FRA:TTX's 1-Year Share Buyback Ratio is ranked worse than
61.12% of 571 companies
in the Medical Devices & Instruments industry
Industry Median: -2.6 vs FRA:TTX: -8.50

Competitive Comparison of Theralase Technologies's 1-Year Share Buyback Ratio

For the Medical Devices subindustry, Theralase Technologies's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Theralase Technologies's 1-Year Share Buyback Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's 1-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Theralase Technologies's 1-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Theralase Technologies 1-Year Share Buyback Ratio Calculation

Theralase Technologies's 1-Year Share Buyback Ratio for the quarter that ended in Dec. 2024 is calculated as

1-Year Share Buyback Ratio	=	(Shares Outstanding (EOP) (Dec. 2023 )	-	Shares Outstanding (EOP) (Dec. 2024 ))	/	Shares Outstanding (EOP) (Dec. 2023 )
	=	(228.461	-	247.780)	/	228.461
	=	-8.5%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theralase Technologies (FRA:TTX) 1-Year Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Theralase Technologies 1-Year Share Buyback Ratio Related Terms

Theralase Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Theralase Technologies Inc (FRA:TTX) » Definitions » 1-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

TLTFF:USA TTX:Germany TLT:Canada

Address

41 Hollinger Road, Toronto, ON, CAN, M4B 3G4

Website

https://www.theralase.com

Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.

Theralase Technologies Headlines

No Headlines